Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.
FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia
December 5th 2023CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.
Read More
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
Navigating HER2+ Early Breast Cancer: Insights Into the Current Treatment Landscape
November 28th 2023In this companion article, Sandra M. Swain, MD, FACP, FASCO, provides insights into effective management of patients with early-stage HER2+ breast cancer and reviews recent data in the evolving treatment landscape.
Read More
Interpreting Safety and Efficacy Data for Tagraxofusp in BPDCN
November 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, moderated discussion of physicians' familiarity with diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.
Read More
Promising Road Lies Ahead for Bispecific Antibody Combinations in Hematologic Malignancies
November 7th 2023As a monotherapy, bispecific antibodies have demonstrated antitumor activity in heavily pretreated patients with B-cell and T-cell hematologic malignancies, but much work is needed to determine the optimal setting.
Read More